HLA-A, -B, -DRB1 alleles and haplotypes frequencies in Moroccan patients with leukemia

Kabbaj, Maria; Oudghiri, Mounia; Naya, Abdellah; Naamane, Hamid; Turk, Joumana El; Bennani, Siham; Hassar, Mohamed

doi:10.1684/abc.2010.0430

Cited by 5 publications

(5 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, they considered this allele as it may be protective against leukemia, whereas DRB1*03, DRB1*04, DRB1*13 has been moderately increased in patients. It therefore might be regarded as susceptible alleles in leukemia disease 26 .This research results was contradictory to another study which find that in CML patients, the haplotype HLA-DRB1 * 0101/DQA1 * 0104/DQB1 * 05011 were significantly more common than controls 14 .…”

Section: Discussioncontrasting

confidence: 68%

HLA DRB1 alleles in association with acute and chronic myeloid leukemia and evaluation of their role as markers for selection of the line of treatment

Morsi

Elgharbawy²,

Hamed³

et al. 2022

Egyptian Journal of Medical Microbiology

View full text Add to dashboard Cite

Background:The genes that encode the human leukocyte antigens (HLA) molecules are the most polymorphic in the human genome and have been considered as possible genetic risk factor in the development of acute and chronic leukemias. Objective: This study aimed at evaluating the role of HLA DRB1 alleles as markers for selection of the line of therapy in Acute myeloid leukemia (AML) and Chronic myeloid leukemia (CML) patients. Methodology: The study was conducted on: 20 AML, 20 CML cases and 20 healthy controls. Typing was done by the sequence-specific primer (PCR-SSP). Results: There was a highly statistical significance association between response to treatment and HLA DRB1 alleles as markers (MCP= .0001) in AML and CML patients. The HLA-DRB1 04*04 allele was found to be associated with good response to therapy in AML patients while, HLA-DRB1 07*15 allele was associated with bad response. In CML patients, HLA-DRB1 03*11 allele was found to be associated with good response to therapy while, HLA-DRB1 alleles 03*04 and 11*15 alleles were equally associated with bad response. Conclusion: Future researches are mandatory especially on larger scale to confirm whether these alleles are protective or even risk alleles regarding both AML and CML.

show abstract

Section: Discussioncontrasting

confidence: 68%

HLA DRB1 alleles in association with acute and chronic myeloid leukemia and evaluation of their role as markers for selection of the line of treatment

Morsi

Elgharbawy²,

Hamed³

et al. 2022

Egyptian Journal of Medical Microbiology

View full text Add to dashboard Cite

show abstract

“…The function of these classes is activate the immune response by encoding membrane glycoproteins that act as mediators in the presentation of antigenic peptides to lymphocytes T CD8+ and T CD4+ respectively [ 12 ]. Thanks to multiple studies on the subject, we know that the HLA complex plays a role in AL pathogenesis [ 13 ].…”

Section: Introductionmentioning

confidence: 99%

“…Therefore, HLA alleles could be important genetic risk factors for AML and ALL patients. A study of a Moroccan population found that HLA-B*44 may be a presumptive predisposing factor in the development of leukemia [ 13 ]. By contrast, a Turkish study found that HLA-B*13 and HLA-B* 40 alleles were negatively associated with AML [ 14 ].…”

Section: Introductionmentioning

confidence: 99%

HLA-B58 and HLA-B27 Play a Role in the Development of Acute Leukemia: A Case Control Study

Habour Nouar,

Yafour,

Youcef

et al. 2024

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

Background: Acute leukemia (AL) constitutes a group of malignant hematological diseases with multifactor origins. Some human leukocyte alleles (HLA) may be important genetic risk factors for development of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). It is still unknown whether there is a relationship between ALL and AML with some alleles of the major histocompatibility complex. Our study looks specifically at western and southwest Algerian populations. Method: Using the polymerase chain reaction with the sequence specific probe (PCR- SSP) method, we investigated the relationship of HLA-B alleles in 163 Algerian AL patients and 293 controls from the same ethnic origin. The study ran from 2013 – 2020. Results: Allele frequencies of HLA-B*27 and HLA-B*58 was higher in AL patients compared with control individuals; p=0.05 and p=0.03 respectively. Interestingly, all patients carrying HLA-B*27 allele and 88% of patients carrying HLA-B*58 allele had AML. However, there were no significant differences when we compared these results with the rest of AL group (HLA-B*X allele) (p=0.387). Response to induction chemotherapy treatment were comparable between the two patient groups 67% and 65% (p=0.978) respectively. Conclusion: These results suggest that the HLA-B*27 and HLA-B*58, may be factors predisposing individuals to acute leukemia, in west and southwest Algerian patients. A large-scale study is still needed to confirm these findings.

show abstract

“…A substantial dataset on HLA-related leukemias is available. Studies have demonstrated links between HLA-DPB1*02:01 (8), DRB1*04 (9-13), DQB1*04 (14), B44 (15), DRB1*13 (15), and predisposition to acute leukemia development. Nevertheless, currently, no HLA allele or haplotype has found clinical application as a diagnostic or prognostic factor in leukemia.…”

Section: Introductionmentioning

confidence: 99%

Frequencies of HLA Alleles in Patients with Acute Lymphoblastic and Myeloid Leukemia

Güleç,

Arslan

2023

Med Sci Discov

View full text Add to dashboard Cite

Objective: Our objective was to investigate the potential correlation between human leukocyte antigens (HLA) - specifically, HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 genes - and patients diagnosed with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). Material and Methods: We conducted an analysis of HLA allele frequencies among 393 patients with ALL, 431 patients with AML, and a control group comprising 564 healthy donors. Additionally, we explored the variation in HLA allele distribution between pediatric and adult patients diagnosed with ALL. Results: In comparison to the donor group, a heightened frequency of HLA-A*32 antigen was observed in AML patients (p=0.015, OR: 1.682). Conversely, the frequencies of HLA-B*55 (p=0.027, OR: 0.545) in ALL patients, HLA-B*14 (p=0.023, OR: 0.397), and HLA-B*55 (p=0.04, OR: 0.604) in AML patients were notably diminished. Notably, there were no discernible differences in HLA Class II allele frequency and analysis between the patient and control groups. Moreover, a significant distinction in the frequencies of HLA-A*25 (p=0.019, OR: 8.426) and DRB1*04 (p=0.049, OR: 1.491) was identified between pediatric patients (n=165) and adult patients (n=228) with ALL. Conclusion: The findings indicate that HLA-A*32 might serve as a genetic predisposing factor for AML, and HLA-A*25 and DRB1*04 could be potential genetic risk factors for pediatric ALL patients. Conversely, HLA-B*55 appears to be a potential protective factor against both forms of acute leukemia.

show abstract

HLA-A, -B, -DRB1 alleles and haplotypes frequencies in Moroccan patients with leukemia

Cited by 5 publications

References 27 publications

HLA DRB1 alleles in association with acute and chronic myeloid leukemia and evaluation of their role as markers for selection of the line of treatment

HLA DRB1 alleles in association with acute and chronic myeloid leukemia and evaluation of their role as markers for selection of the line of treatment

HLA-B58 and HLA-B27 Play a Role in the Development of Acute Leukemia: A Case Control Study

Frequencies of HLA Alleles in Patients with Acute Lymphoblastic and Myeloid Leukemia

Contact Info

Product

Resources

About

HLA-A, -B, -DRB1 alleles and haplotypes frequencies in Moroccan patients with leukemia

Cited by 5 publications

References 27 publications

HLA DRB1 alleles in association with acute and chronic myeloid leukemia and evaluation of their role as markers for selection of the line of treatment

HLA DRB1 alleles in association with acute and chronic myeloid leukemia and evaluation of their role as markers for selection of the line of treatment

HLA-B*58 and HLA-B*27 Play a Role in the Development of Acute Leukemia: A Case Control Study

Frequencies of HLA Alleles in Patients with Acute Lymphoblastic and Myeloid Leukemia

Contact Info

Product

Resources

About

HLA-B58 and HLA-B27 Play a Role in the Development of Acute Leukemia: A Case Control Study